ISEC Healthcare Ltd (40T) Fair Value & Analysis
Healthcare · SG · Market cap 181M SGD
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.3000 SGD – 0.3634 SGD · fair‑value band 0.3100 SGD – 0.5800 SGD · the 0.3150 SGD price screens below the 0.4400 SGD fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ISEC Healthcare Ltd (40T) currently trades at 0.3150 SGD, while our model-based Fair Value estimate is 0.4400 SGD — implying the stock looks roughly 39.7% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, ISEC Healthcare Ltd generated revenue of 80.0M SGD at a net margin of 16.4%. Revenue grew 4.3% year over year. It earns a return on equity of 13.0%. The stock trades on a trailing P/E of 15.8. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
ISEC Healthcare Ltd., an investment holding company, provides medical care, consultancy, treatment, and surgery services in the field of ophthalmology in Singapore, Malaysia, and Myanmar. It operates in two segments, Specialised Health Services and General Health Services. The company offers various services, including cataract and intraocular lens implant, refractive surgery, vitreous and retinal diseases, adult strabismus and paediatric ophthalmology, glaucoma diagnostics and therapeutics, medical retinal diseases, uveitis, optometry and orthoptics, oculoplastics, facial cosmetics, and aesthetic surgery, as well as cornea, external eye disease, and anterior segment. It also provides general medical and procedural treatment services; and operates eye care centers. The company was founded in 2007 and is headquartered in Singapore. ISEC Healthcare Ltd. operates as a subsidiary of Aier Eye International (Singapore) Pte. Ltd.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ISEC Healthcare Ltd reported revenue of 79.2M SGD in FY2025 versus 40.5M SGD in FY2021, a compound +18.3%/yr. Reported net income was 13.4M SGD in FY2025, compounding +18.0%/yr from FY2021.
Is 40T fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ISEC Healthcare Ltd (40T) undervalued?
What is the fair value of 40T?
What is the quality score of 40T?
What is the revenue of ISEC Healthcare Ltd (40T)?
What is the net profit margin of 40T?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.